3 Things to Loathe About GlaxoSmithKline plc (ADR) (GSK)

LONDON — There are things to love and loathe about most companies. Today, I’m going to tell you about three things to loathe about GlaxoSmithKline plc (ADR) (NYSE:GSK).

I’ll also be asking whether these negative factors make this FTSE 100 pharmaceuticals giant a poor investment today.

GlaxoSmithKline plc (ADR) (NYSE:GSK)

Long-term returns
GlaxoSmithKline plc (ADR) (NYSE:GSK)’s long-run total return for shareholders (capital appreciation and dividends over the past 10 years) has lagged behind that of the average FTSE 100 company. Furthermore, as the table below shows, GlaxoSmithKline plc (ADR) (NYSE:GSK) has been one of the poorer performers among its European big pharma peers.

Company Total return
over 10 years
(annualized)
Roche 9.4%
Novartis 8.6%
Sanofi 8.3%
GlaxoSmithKline 5.9%
AstraZeneca 5.3%

Margin pressures
GlaxoSmithKline plc (ADR) (NYSE:GSK), like all the established big pharma companies, faces what it calls ”intense competition” from generic products within all of its major markets. This is particularly true of the U.S., where GlaxoSmithKline plc (ADR) (NYSE:GSK) has its highest turnover and margins, both of which are now under pressure from generics.

The U.S. accounts for almost a third of group turnover, and in addition to the squeeze from generics, the country’s health care reforms are also putting pressure on GlaxoSmithKline plc (ADR) (NYSE:GSK)’s margins.

Finally, the company’s diversification into consumer health care has implications for group margins: the operating margin for pharmaceuticals and vaccines is running at over 36%, but the margin within the over-the-counter business is half that.

Concentration of risk
Another issue for GSK in the U.S. is that the sale of most of its products are made to a small number of wholesalers. In fact, more than 80% of the group’s U.S. pharmaceuticals and vaccines turnover comes from just three wholesalers.

Trade receivables due from these three (that’s the money they owe GSK) amounted to 815 million pounds — the equivalent of 17 pence a share — at the latest reckoning. This concentration of credit risk could potentially, as GSK says, ”materially and adversely affect the Group’s financial results.”

A poor investment?
Many of the issues GSK faces are felt across the whole sector. Whether the sum of factors that constitute GSK’s particular variation on the theme put the company in a better or worse position than its peers is a moot point.

Two of the world’s top investors aren’t prepared to argue it. Instead, they prefer to hedge their bets in a sector where the theoretical strength of the different companies’ drugs pipelines isn’t a reliable guide to which products will actually turn out to be the biggest winners.

Legendary U.S. investor Warren Buffett and renowned U.K. fund manager Neil Woodford both choose to invest across several big pharma companies.

The article 3 Things to Loathe About GlaxoSmithKline originally appeared on Fool.com.

G.A. Chester has no position in any stocks mentioned. The Motley Fool recommends GlaxoSmithKline.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!